Loading
The one regimen proven in a randomised trial to help HER2-positive brain metastases, extending survival in those patients by six months.
This combination gives tucatinib with trastuzumab and capecitabine to patients with HER2-positive breast cancer and brain metastases. Tucatinib is a small, HER2-selective molecule that crosses the blood-brain barrier, capecitabine adds a cytotoxic effect that is active in the central nervous system, and trastuzumab maintains systemic control. In the phase 3 HER2CLIMB trial, which included dedicated analyses of patients with brain metastases, the regimen improved intracranial progression-free survival and overall survival and produced responses in both untreated and previously treated brain lesions. It remains the one regimen shown in a randomised trial to help HER2-positive brain metastases, and it allows whole-brain radiation to be deferred in selected cases.
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab.
Shares HER2CLIMB, HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab.
Shares HER2CLIMB, HER2-positive brain metastases, HER2-positive breast cancer with brain metastases, Tucatinib.
Shares HER2-positive breast cancer with brain metastases, Tucatinib, Trastuzumab, HER2-positive breast cancer.
Shares Tucatinib, Trastuzumab, HER2-positive breast cancer.
Shares HER2CLIMB, HER2-positive brain metastases.
Shares HER2-positive breast cancer with brain metastases, Tucatinib, HER2-positive breast cancer.
Shares HER2-positive brain metastases, HER2-positive breast cancer with brain metastases, HER2-positive breast cancer.